#ORPH Open Orphan Plc – £1.5m Contract renewal for Venn Life Sciences November 15, 2021 – Posted in: Blog, Open Orphan (ORPH)

(AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces that Venn Life Sciences (“Venn”), a subsidiary of Open Orphan, has signed a contract renewal with a major global pharmaceutical client worth £1.5m over two years. The renewed contract will commence in January 2022, with the Venn team in Breda providing dedicated clinical pharmacokinetics (‘PK’) support to this leading global pharmaceutical client on an array of drug development programmes, to study…

Open Orphan #ORPH – Major year-on-year revenue growth and profitable H1 2021 performance following a year of turnaround and transition in 2020 September 20, 2021 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces its unaudited interim results for the six months ended 30 June 2021. These results show a continued pattern of profitability from Q4 2020 to a firmly profitable position delivering a positive EBITDA profit of £2.1 million compared to an EBITDA loss of £4.1 million in H1 2020. We…

Open Orphan #ORPH – DNDi Phase II trial to support river blindness drug July 29, 2021 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan plc (AIM: ORPH), a rapidly growing specialist clinical research organisation (CRO) which is the world leader in testing vaccines and antivirals using human challenge clinical trials, announces a contract to supply consultancy services to support a Phase II trial in Onchocerciasis Disease, an infectious disease commonly known as river blindness. Venn Life Sciences (“Venn”), a subsidiary of Open Orphan, will provide Data Management & Biostatistics services to support the Phase II trial of…

Open Orphan (ORPH) Final Results to 31 December 2020 June 17, 2021 – Posted in: Blog, Open Orphan (ORPH)

Final Results to 31 December 2020 Important year of transition following the various merger and acquisition activities in 2019 and January 2020 Open Orphan (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces its audited results for the 12 months to 31 December 2020. Following the acquisition of hVIVO in January of last year, 2020 was a…

Open Orphan #ORPH – Exercise of Warrants & TVR June 11, 2021 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials , has received notice of exercise of warrants by investors, who participated in the Venn loan note financing in December 2018, over 404,806 ordinary shares of 0.1 pence each in the capital of the Company (“Ordinary Shares”) at a price of 0.1 pence per share for 143,312 Ordinary…

Open Orphan #ORPH – New contract win with Oxford BioTherapeutics March 9, 2021 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services CRO and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces its subsidiary Venn Life Sciences (“Venn”) has been awarded a contract for a study with Oxford BioTherapeutics, a clinical stage oncology company with a pipeline of immune-oncology and antibody-drug conjugate-based therapies. This is a phase I, open-label, dose finding study which will be used to assess the safety, tolerability,…

Open Orphan #ORPH – Exercise of Investor Warrants by Investors, Issue of Shares and TVR February 3, 2021 – Posted in: Open Orphan (ORPH)

Open Orphan (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organization (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials , has received notice of exercise of warrants by investors who participated in the Venn loan note financing in December 2018 over 1,349,349 ordinary shares of 0.1 pence each in the capital of the Company (“Ordinary Shares”) at a price of 0.1 pence per share for 477,703 Ordinary Shares and…

Open Orphan #ORPH – Contract extension with Carna Biosciences February 1, 2021 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces a further contract renewal with Carna Biosciences, Inc. (“Carna”), extending its integrated drug development consultancy services with Venn Life Sciences (“Venn”), part of Open Orphan plc. Carna Biosciences is a clinical-stage biopharmaceutical company which focuses on the discovery and development of innovative therapies to treat serious unmet…

Open Orphan #ORPH – Contract renewal with top-3 global pharmaceutical client January 6, 2021 – Posted in: Open Orphan (ORPH)

Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services CRO and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces a further contract renewal with a major top-3 global pharmaceutical client extending its consultancy services to end of December 2021. This follows on from the announcement made on 22 December 2020 regarding the same client and demonstrates the repeat business that Venn Life Sciences continues to win from…

Open Orphan #ORPH – Successful completion of PrEP Biopharm Toxicology study for respiratory ‘viral mimic’ December 23, 2020 – Posted in: Open Orphan (ORPH)

Phase IIb study to validate efficacy of PrEP-001 against circulating respiratory viruses such as COVID-19, flu and the common cold Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services CRO which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials, announces that drug development company PrEP Biopharm Limited (“PrEP Biopharm”), which is 62.6% owned by Open Orphan, has successfully completed a 12-week toxicology study for its novel…

1
2
3
4
Next
Last »